148 related articles for article (PubMed ID: 38135373)
21. Unique ethnic features of
Choi EJ; Cho YU; Hur EH; Jang S; Kim N; Park HS; Lee JH; Lee KH; Kim SH; Hwang SH; Seo EJ; Park CJ; Lee JH
Haematologica; 2022 Feb; 107(2):510-518. PubMed ID: 33626862
[TBL] [Abstract][Full Text] [Related]
22. Clinical features and outcomes of patients with Shwachman-Diamond syndrome and myelodysplastic syndrome or acute myeloid leukaemia: a multicentre, retrospective, cohort study.
Myers KC; Furutani E; Weller E; Siegele B; Galvin A; Arsenault V; Alter BP; Boulad F; Bueso-Ramos C; Burroughs L; Castillo P; Connelly J; Davies SM; DiNardo CD; Hanif I; Ho RH; Karras N; Manalang M; McReynolds LJ; Nakano TA; Nalepa G; Norkin M; Oberley MJ; Orgel E; Pastore YD; Rosenthal J; Walkovich K; Larson J; Malsch M; Elghetany MT; Fleming MD; Shimamura A
Lancet Haematol; 2020 Mar; 7(3):e238-e246. PubMed ID: 31879230
[TBL] [Abstract][Full Text] [Related]
23. The utility of a myeloid mutation panel for the diagnosis of myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasm.
Ibrar W; Zhang W; Cox JL; Cushman-Vokoun A; Fu K; Greiner TC; Yuan J
Int J Lab Hematol; 2021 Dec; 43(6):1501-1509. PubMed ID: 34270867
[TBL] [Abstract][Full Text] [Related]
24. Clinical and pathologic challenges of clonal cytopenia of undetermined significance.
Weinberg OK
Int J Lab Hematol; 2021 Jul; 43 Suppl 1():82-85. PubMed ID: 34288451
[TBL] [Abstract][Full Text] [Related]
25. Excellent Prognosis of Low-Risk Myelodysplastic Syndromes (MDS) Without Detectable Myeloid-Related Mutations.
Polprasert C; Niparuck P; Rattanathammethee T; Chuncharunee S; Kobbuaklee S; Songserm K; Suksusut A; Trithiphen S; Lanamtieng T; Kongkiatkamon S; Chanswangphuwana C; Lawasut P; Bunworasate U; Rojnuckarin P
Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):e293-e299. PubMed ID: 34840089
[TBL] [Abstract][Full Text] [Related]
26. The impact of cytotoxic therapy on the risk of progression and death in clonal cytopenia(s) of undetermined significance.
Li M; Baranwal A; Gurney M; Shah SN; Al-Kali A; Alkhateeb H; Foran J; Arana Yi C; Ongie L; Chen D; Mangaonkar A; McCullough K; Tefferi A; Lasho T; Finke C; Patnaik MM; Shah MV
Blood Adv; 2024 Jun; 8(12):3130-3139. PubMed ID: 38564774
[TBL] [Abstract][Full Text] [Related]
27. Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population.
van Zeventer IA; de Graaf AO; Salzbrunn JB; Nolte IM; Kamphuis P; Dinmohamed A; van der Reijden BA; Schuringa JJ; Jansen JH; Huls G
Cancer Cell; 2023 Jun; 41(6):1017-1031.e4. PubMed ID: 37146604
[TBL] [Abstract][Full Text] [Related]
28. The International Consensus Classification of myelodysplastic syndromes and related entities.
Hasserjian RP; Orazi A; Orfao A; Rozman M; Wang SA
Virchows Arch; 2023 Jan; 482(1):39-51. PubMed ID: 36287260
[TBL] [Abstract][Full Text] [Related]
29. The genetic analysis of Chinese patients with clonal cytopenias using targeted next-generation sequencing.
Zhang L; Shi Y; Chen Y; Tao S; Shi W; He Z; Chen K; Wang C; Yu L
Mol Cytogenet; 2021 Nov; 14(1):52. PubMed ID: 34794475
[TBL] [Abstract][Full Text] [Related]
30. Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms.
Shah MV; Mangaonkar AA; Begna KH; Alkhateeb HB; Greipp P; Nanaa A; Elliott MA; Hogan WJ; Litzow MR; McCullough K; Tefferi A; Gangat N; Patnaik MM; Al-Kali A; He R; Chen D
Blood Cancer J; 2022 Jul; 12(7):106. PubMed ID: 35803921
[TBL] [Abstract][Full Text] [Related]
31. Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2
Todisco G; Creignou M; Gallì A; Guglielmelli P; Rumi E; Roncador M; Rizzo E; Nannya Y; Pietra D; Elena C; Bono E; Molteni E; Rosti V; Catricalá S; Sarchi M; Dimitriou M; Ungerstedt J; Vannucchi AM; Hellström-Lindberg E; Ogawa S; Cazzola M; Malcovati L
Leukemia; 2021 Aug; 35(8):2371-2381. PubMed ID: 33349666
[TBL] [Abstract][Full Text] [Related]
32. The Application of NextGen Sequencing in the Diagnosis of Myeloid Neoplasms in Myeloma Patients With Cytopenia.
Song J; Zhang H; Dong N; Zhang X; Hussaini M; Jain A; Moscinski L; Shain K; Baz R; Alsina M; Nishihori T; Zhang L
Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):e414-e426. PubMed ID: 34998786
[TBL] [Abstract][Full Text] [Related]
33. ICUS/CCUS/CHIP: basics & beyond.
Jain M; Tripathi A
Expert Rev Hematol; 2017 Oct; 10(10):915-920. PubMed ID: 28832236
[TBL] [Abstract][Full Text] [Related]
34. Clinical implications of myeloid malignancy‑related somatic mutations in aplastic anemia.
Liu L; Zhang D; Fu Q; Wang J; Yu J; Chen D; Wang F; Guo R; Xie X; Jiang Z; Li Y
Clin Exp Med; 2023 Dec; 23(8):4473-4482. PubMed ID: 37087521
[TBL] [Abstract][Full Text] [Related]
35. LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome.
Kaastrup K; Gillberg L; Mikkelsen SU; Ørskov AD; Schöllkopf C; Mortensen BK; Porse B; Hansen JW; Grønbæk K
Clin Epigenetics; 2023 May; 15(1):91. PubMed ID: 37237325
[TBL] [Abstract][Full Text] [Related]
36. Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.
Steensma DP; Abedi M; Bejar R; Cogle CR; Foucar K; Garcia-Manero G; George TI; Grinblatt D; Komrokji R; Ma X; Maciejewski J; Pollyea DA; Savona MR; Scott B; Sekeres MA; Thompson MA; Swern AS; Nifenecker M; Sugrue MM; Erba H
BMC Cancer; 2016 Aug; 16():652. PubMed ID: 27538433
[TBL] [Abstract][Full Text] [Related]
37. The Clinical Challenge of Idiopathic Cytopenias of Undetermined Significance (ICUS) and Clonal Cytopenias of Undetermined Significance (CCUS).
Steensma DP
Curr Hematol Malig Rep; 2019 Dec; 14(6):536-542. PubMed ID: 31696381
[TBL] [Abstract][Full Text] [Related]
38. DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease.
Quesada AE; Routbort MJ; DiNardo CD; Bueso-Ramos CE; Kanagal-Shamanna R; Khoury JD; Thakral B; Zuo Z; Yin CC; Loghavi S; Ok CY; Wang SA; Tang Z; Bannon SA; Benton CB; Garcia-Manero G; Kantarjian H; Luthra R; Medeiros LJ; Patel KP
Am J Hematol; 2019 Jul; 94(7):757-766. PubMed ID: 30963592
[TBL] [Abstract][Full Text] [Related]
39. Routine clinical mutation profiling using next generation sequencing and a customized gene panel improves diagnostic precision in myeloid neoplasms.
Bartels S; Schipper E; Hasemeier B; Kreipe H; Lehmann U
Oncotarget; 2016 May; 7(21):30084-93. PubMed ID: 27029036
[TBL] [Abstract][Full Text] [Related]
40. Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies.
Stengel A; Baer C; Walter W; Meggendorfer M; Kern W; Haferlach T; Haferlach C
Blood Adv; 2021 Nov; 5(21):4426-4434. PubMed ID: 34570179
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
